NCT04571567View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Psoriasis
Interventions
DRUG

Secukinumab

Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.

Trial Locations (1)

10023

Mount Sinai West Dermatolgy, New York

All Listed Sponsors
lead

Saakshi Khattri

OTHER

NCT04571567 - A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter